Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $147.62 billion. The enterprise value is $199.27 billion.
| Market Cap | 147.62B |
| Enterprise Value | 199.27B |
Important Dates
The last earnings date was Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | May 8, 2026 |
Share Statistics
Pfizer has 5.70 billion shares outstanding. The number of shares has increased by 0.26% in one year.
| Current Share Class | 5.70B |
| Shares Outstanding | 5.70B |
| Shares Change (YoY) | +0.26% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 68.38% |
| Float | 5.69B |
Valuation Ratios
The trailing PE ratio is 19.76 and the forward PE ratio is 9.09.
| PE Ratio | 19.76 |
| Forward PE | 9.09 |
| PS Ratio | 2.33 |
| Forward PS | 2.40 |
| PB Ratio | 1.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.57 |
| P/OCF Ratio | 12.32 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.83, with an EV/FCF ratio of 21.01.
| EV / Earnings | 26.60 |
| EV / Sales | 3.15 |
| EV / EBITDA | 7.83 |
| EV / EBIT | 10.54 |
| EV / FCF | 21.01 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.25 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 2.45 |
| Debt / FCF | 6.83 |
| Interest Coverage | 7.04 |
Financial Efficiency
Return on equity (ROE) is 8.31% and return on invested capital (ROIC) is 12.72%.
| Return on Equity (ROE) | 8.31% |
| Return on Assets (ROA) | 5.69% |
| Return on Invested Capital (ROIC) | 12.72% |
| Return on Capital Employed (ROCE) | 10.91% |
| Weighted Average Cost of Capital (WACC) | 5.33% |
| Revenue Per Employee | $844,200 |
| Profits Per Employee | $99,880 |
| Employee Count | 75,000 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.48 |
Taxes
In the past 12 months, Pfizer has paid $384.00 million in taxes.
| Income Tax | 384.00M |
| Effective Tax Rate | 4.86% |
Stock Price Statistics
The stock price has increased by +12.41% in the last 52 weeks. The beta is 0.31, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +12.41% |
| 50-Day Moving Average | 26.81 |
| 200-Day Moving Average | 25.80 |
| Relative Strength Index (RSI) | 44.16 |
| Average Volume (20 Days) | 36,706,791 |
Short Selling Information
The latest short interest is 140.32 million, so 2.46% of the outstanding shares have been sold short.
| Short Interest | 140.32M |
| Short Previous Month | 132.47M |
| Short % of Shares Out | 2.46% |
| Short % of Float | 2.47% |
| Short Ratio (days to cover) | 3.98 |
Income Statement
In the last 12 months, Pfizer had revenue of $63.32 billion and earned $7.49 billion in profits. Earnings per share was $1.31.
| Revenue | 63.32B |
| Gross Profit | 47.36B |
| Operating Income | 18.91B |
| Pretax Income | 7.91B |
| Net Income | 7.49B |
| EBITDA | 25.46B |
| EBIT | 18.91B |
| Earnings Per Share (EPS) | $1.31 |
Balance Sheet
The company has $13.08 billion in cash and $64.73 billion in debt, with a net cash position of -$51.65 billion or -$9.06 per share.
| Cash & Cash Equivalents | 13.08B |
| Total Debt | 64.73B |
| Net Cash | -51.65B |
| Net Cash Per Share | -$9.06 |
| Equity (Book Value) | 90.40B |
| Book Value Per Share | 15.81 |
| Working Capital | 8.47B |
Cash Flow
In the last 12 months, operating cash flow was $11.98 billion and capital expenditures -$2.50 billion, giving a free cash flow of $9.48 billion.
| Operating Cash Flow | 11.98B |
| Capital Expenditures | -2.50B |
| Depreciation & Amortization | 6.55B |
| Net Borrowing | 2.23B |
| Free Cash Flow | 9.48B |
| FCF Per Share | $1.66 |
Margins
Gross margin is 74.80%, with operating and profit margins of 29.87% and 11.83%.
| Gross Margin | 74.80% |
| Operating Margin | 29.87% |
| Pretax Margin | 12.49% |
| Profit Margin | 11.83% |
| EBITDA Margin | 40.21% |
| EBIT Margin | 29.87% |
| FCF Margin | 14.98% |
Dividends & Yields
This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 6.64%.
| Dividend Per Share | $1.72 |
| Dividend Yield | 6.64% |
| Dividend Growth (YoY) | 1.18% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 131.03% |
| Buyback Yield | -0.26% |
| Shareholder Yield | 6.38% |
| Earnings Yield | 5.07% |
| FCF Yield | 6.42% |
Analyst Forecast
The average price target for Pfizer is $29.19, which is 12.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.19 |
| Price Target Difference | 12.70% |
| Analyst Consensus | Buy |
| Analyst Count | 29 |
| Revenue Growth Forecast (5Y) | -1.42% |
| EPS Growth Forecast (5Y) | 8.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 1, 1999. It was a forward split with a ratio of 3:1.
| Last Split Date | Jul 1, 1999 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Pfizer has an Altman Z-Score of 2.17 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 6 |